Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies
Frey, M.K, Ward, N.M, Caputo, T.A, Taylor, J, Worley, M.J, Slomovitz, B.M
Published in Gynecologic oncology (01.04.2012)
Published in Gynecologic oncology (01.04.2012)
Get full text
Journal Article
Analyzing the learning curve of robotic-assisted sentinel lymph node dissection for endometrial cancer
Hughes, P, Graebe, K, Tchabo, N, Tobias, D.H, Heller, P.B, Slomovitz, B.M
Published in Gynecologic oncology (01.06.2014)
Published in Gynecologic oncology (01.06.2014)
Get full text
Journal Article
Does ultrastaging improve detection of micrometastasis for early-stage endometrial cancer?
Hughes, P, Edmee, S, Tchabo, N, Tobias, D.H, Heller, P.B, Slomovitz, B.M
Published in Gynecologic oncology (01.06.2014)
Published in Gynecologic oncology (01.06.2014)
Get full text
Journal Article
Impact of molecular testing in clinical practice of gynecologic cancers
Hunter, T., Schlumbrecht, M.P., Dimentstein, K., Slomovitz, B.M., Huang, M.
Published in Gynecologic oncology (01.06.2018)
Published in Gynecologic oncology (01.06.2018)
Get full text
Journal Article
Prevalence of high risk non-vaccine type HPV among U.S. women who received Cervarix or Gardasil: NHANES 2009-2014
Wong, A.J., Nigh, E.D., Dimentstein, K., Balise, R.R., Slomovitz, B.M.
Published in Gynecologic oncology (01.06.2018)
Published in Gynecologic oncology (01.06.2018)
Get full text
Journal Article
734P Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Mathews, C., Koliadi, A., Gilbert, L., Slomovitz, B.M., Frühauf, F., Buttin, B., Özgül, N., Monk, B.J., Fountzilas, G., Billingsley, C., Trinidad, J., Braly, P., Boone, J., Black, D., Sharma, S., Lubinga, S.J., Sharpe, D.J., Ronzino, G., Powell, M.A., Mirza, M.R.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
Lee, J-M., MacLaughlan, S., Matei, D., Song, M., Brubaker, L., Rimmel, B., Eskander, R.N., Kyi, C., Williams, H., Duska, L., Musa, F., Coleman, R.L., Slomovitz, B.M., Gamelin, E.C., Cuillerot, J-M., Phadnis, M.M., Guercio, B., Crafton, S., Konstantinopoulos, P.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Mirza, M.R., Sharma, S., Herrstedt, J., Shahin, M.S., Cibula, D., Fleming, E., Raspagliesi, F., Buscema, J., Hanker, L.C., Coleman, R.L., Boere, I.A., Schneider, K., Gilbert, L., Slomovitz, B.M., Teneriello, M.G., Powell, M.A., Ghosh, S., Stevens, S., Ring, K., Stuckey, A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Slomovitz, B.M., Raaschou-Jensen, N., Coleman, R.L., Gilbert, L., Powell, M.A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A.A., Ataseven, B., Black, D., Wymenga, M., Billingsley, C., Willmott, L.J., McCourt, C., Podzielinski, I., Doehring, O., Garside, J., Herzog, T.J., Mirza, M.R.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Mirza, M.R., Chase, D., Slomovitz, B.M., Christensen, R.D., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L.M., Hanker, L.C., Stuckey, A., Boere, I.A., Gold, M., Gill, S.E., Monk, B.J., He, Z., Stevens, S., Coleman, R.L., Powell, M.A.
Published in Annals of oncology (01.05.2023)
Published in Annals of oncology (01.05.2023)
Get full text
Journal Article
Racial and ethnic disparities among patients with low-grade serous ovarian carcinoma
Siemon, J., George, S., Huang, M., Slomovitz, B.M., Pearson, J.M., Schlumbrecht, M.P.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article
LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Van Gorp, T., Rob, L., Lu, W., Backes, F., Ortaç, F., Hasegawa, K., Hietanen, S.H., Savarese, A., Laenen, A., Kim, Y.M., Bodnar, L., Barretina Ginesta, M.P., Gilbert, L., Pothuri, B., Chen, X., Lichfield, J., Wang, W., Orlowski, R.J., Lortholary, A., Slomovitz, B.M.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Lorusso, D., Mirza, M.R., Martin-Babau, J., Bologna, A., Barretina Ginesta, M.P., Marmé, F., Wampfler, J., Cibula, D., Zhu, J., Hasegawa, K., Samouëlian, V., Lee, J-Y., Casarotto, F.C., Antill, Y., Lightfoot, M., Herzog, T.J., Woodhouse, K., Cui, Y., Slomovitz, B.M., Monk, B.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Danska-Bidzinska, A., Makker, V., Salutari, V., Ayhan, A., Romero, I., Levy, T., McCormack, M., Baurain, J-F., Mach, P., Cadoo, K.A., Mackay, H., Friedlander, M.L., Santin, A.D., Slomovitz, B.M., Miller, D.S., McKenzie, J., Yao, L., Khemka, V., Nogueira-Rodrigues, A., Marth, C.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Blank, S.V., McCollum, M., Anderson, C., Pennington, K., Salinas, E., Richardson, D.L., Slomovitz, B.M., Kim, B-G., Liu, J., Mori, M., Guette, P.L. Ramos, Joseph de Pádua, C., Martinez-Garcia, J., Papadimitriou, C., Grisan, K., Póka, R.L., Kowgier, M., Del Rosario, P.M.D., Van Nieuwenhuysen, E., Westin, S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Fujiwara, K., Slomovitz, B.M., Gonzalez Martin, A., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Vergote, I.B.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Vergote, I.B., Gonzalez Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Slomovitz, B.M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study
Slomovitz, B.M., Filiaci, V.L., Coleman, R.L., Walker, J.L., Fleury, A.C., Holman, L.L., Miller, D.S.
Published in Gynecologic oncology (01.06.2018)
Published in Gynecologic oncology (01.06.2018)
Get full text
Journal Article